Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Aldesleukin (compound)


PubChem Substance
Name: aldesleukin
PubChem Substance ID: 10105
Synonyms:
C07903; Interleukin-2; Aldesleukin; 110942-02-4
DrugBank
Identification
Name: aldesleukin
Name (isomeric): DB00041
Drug Type: biotech
Synonyms:
Interleukin-2 precursor; TCGF; IL-2; T-cell growth factor
Brand: Proleukin (Chiron Corp), Proleukin
Category: Antineoplastic Agents
CAS number: 85898-30-2
Pharmacology
Indication: For treatment of adults with metastatic renal cell carcinoma.
Pharmacology:
Used to treat renal cell carcinoma, Aldesleukin induces the enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines, the enhancement of lymphocyte cytotoxicity, the induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and the induction of interferon-gamma prod...
show more »
Mechanism of Action:
Aldesleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling...
show more »
Route of elimination: The pharmacokinetic profile of Proleukin is characterized by high plasma concentrations following a short IV infusion, rapid distribution into the extravascular space and elimination from the body by metabolism in the kidneys with little or no bioactive protein excreted in the urine. Following the initial rapid organ distribution, the primary route of clearance of circulating proleukin is the kidney. Greater than 80% of the amount of Proleukin distributed to plasma, cleared from the circulation and presented to the kidney is metabolized to amino acids in the cells lining the proximal convoluted tubules.
Half Life: 13 min-85 min
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
ClobetasolCorticosteroids such as clobetasol may diminish the antineoplastic effect of aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin.
ClocortoloneCorticosteroids such as clocortolone may diminish the antineoplastic effect of aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin.
CorticotropinCorticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin.

Targets